Astellas’ focus will be on developing breakthrough products in the areas of immunology, infectious disease, dermatology, urology and cardiovascular disease, while continuing to explore unmet needs in other areas.
The company will continue to support its mainstay prescription products including Prograf, VESIcare, Protopic, Adenoscan, AmBisome and Flomax. In May, Mycamine will be the first product launched under the Astellas name, for the treatment of candida fungal infections.
The Astellas worldwide headquarters is located in Tokyo. In the US, Astellas will operate commercially under the name Astellas Pharma US, Inc, with headquarters located in Deerfield, Illinois, becoming a larger presence in the growing pharmaceutical industry in Illinois. Its European regional office is based in London, UK and additional Asian operations are located in China, Korea, Taiwan, Thailand, Philippines and Indonesia.